崔永萍教授  深圳北京大学香港科技大学医学中心肿瘤研究所所长，深圳湾实验室肿瘤研究所詹启敏课题组co-PI，研究员，博士生导师。享受国务院政府特殊津贴专家，入选国家“万人计划”领军人才、国家百千万人才工程国家级人选、国家有突出贡献中青年专家、深圳市国家级领军人才、全国巾帼建功标兵。

研究领域：消化系统等常见恶性肿瘤癌变、转移和耐药机理，筛选分子标志物和开发诊疗新策略

个人学术简介：

崔永萍团队长期致力于破译中国食管鳞癌的致病机制，建立其精确分型体系，筛选有效的早诊分子标志物和治疗靶点。近年来，在食管鳞癌研究领域取得了显著的成就，通过多组学研究和分子机制的深入解析，建立了全球最大的食管鳞癌单病种多模态组学数据分析平台，首次建立了中国人群食管鳞癌的精确分型体系，提出不同亚型的精准治疗策略，推动了食管癌精准诊疗和新药研发的发展，为建立食管癌诊疗的“中国方案”做出了重要贡献。相关研究成果发表在Cancer Cell、Cell Research、Signal Transduction and Targeted Therapy、Nature communications、National Science Review等国家知名期刊，论文近5年被SCI他引超过1000次，多次被Science、Nature期刊文章所引用。主持或参加国家级科研项目16项，包括国家重点研发计划“常见多发病防治研究”重点专项、国家自然科学基金重点项目、科技部“重大慢性非传染性疾病防控研究”重点专项等；且先后承担和完成省级科研项目和人才类项目25项，包括深圳市医学科学院医学研究专项资金项目等。荣获中国抗癌协会科技二等奖等。担任国家自然科学基金、教育部科技项目等评审专家。

代表性论文：

【1】Yong Zhou#, Shanlan Mo#, Heyang Cui#, Ruifang Sun#, Weimin Zhang#, Xiaofei Zhuang#, Enwei Xu, Hongyi Li, Yikun Cheng, Yongsheng Meng, Meilin Liu, Ting Yan, Huijuan Liu, Ling Zhang, Bin Yang, Yanfeng Xi, Shubin Wang, Xiaolong Cheng, ShuaiCheng Li, Zhihua Liu*, Qimin Zhan*, Zheng Hu*, Yongping Cui*. Immune-tumor interaction dictates spatially directed evolution of esophageal squamous cell carcinoma.  National Science Review. 2024; nwae150.  IF=16.3 

【2】Xuehan Zhuang, Rui Ye, Yong Zhou, Matthew Yibo Cheng, Heyang Cui, Longlong Wang, Shuangping Zhang, Shubin Wang, Yongping Cui*, Weimin Zhang*. Leveraging new methods for comprehensive characterization of mitochondrial DNA in esophageal squamous cell carcinoma. Genome Medicine. 2024 Apr 02; 16(50): 1-19.  IF=10.4

【3】Zhihua Liu*, Yahui Zhao, Pengzhou Kong, Yuhao Liu, Jing Huang, Enwei Xu, Wenqing Wei, Guangyu Li, Xiaolong Cheng, Liyan Xue, Yi Li, Hongyan Chen, Shuqing Wei, Ruifang Sun, Heyang Cui, Yongsheng Meng, Meilin Liu, Yang Li, Riyue Feng, Xiao Yu, Rui Zhu, Yenan Wu, Lei Li, Bin Yang, Yanchun Ma, Jiawei Wang, Wenjie Zhu, Dongjie Deng, Yanfeng Xi, Fang Wang, Hongyi Li, Shiping Guo, Xiaofei Zhuang, Xiaoyue Wang, Yuchen Jiao*, Yongping Cui*, Qimin Zhan*, Integrated Multi-omics Profiling Yields a Clinically-Relevant Molecular Classification for Esophageal Squamous Cell Carcinoma. Cancer Cell. 2023 Jan 9,41, 1-15. IF=48.8

【4】Heyang Cui#, Yong Zhou#, Fang Wang#, Caixia Cheng#, Weimin Zhang#, Ruifang Sun#, Ling Zhang#, Yanghui Bi, Min Guo, Yan Zhou, Xinhui Wang, Jiaxin Ren, Ruibing Bai, Ning Ding, Chen Cheng, Longlong Wang, Xuehan Zhuang, Mingwei Gao, Yongjia Weng, Yueguang Wu, Huijuan Liu, Shuaicheng Li, Shubin Wang, Xiaolong Cheng, Yongping Cui*, Zhihua Liu*& Qimin Zhan*.Characterization of Somatic Structural Variations in 528 Chinese individuals with Esophageal Squamous Cell Carcinoma. Nature Communications.2022 Oct 22;13(1):6296.  IF=14.7

【5】Yongping Cui#, Hongyan Chen#, Ruibin Xi#, Heyang Cui#, Yahui Zhao#, Enwei Xu#, Ting Yan, Xiaomei Lu, Furong Huang, Pengzhou Kong, Yang Li, Xiaolin Zhu, Jiawei Wang, Wenjie Zhu, Jie Wang, Yanchun Ma, Yong Zhou, Shiping Guo,Ling Zhang, Yiqian Liu, Bin Wang, Yanfeng Xi, Ruifang Sun, Xiao Yu, Yuanfang Zhai, Fang Wang, Jian Yang, Bin Yang, Caixia Cheng, Jing Liu, Bin Song, Hongyi Li, Yi Wang, Yingchun Zhang, Xiaolong Cheng, Qimin Zhan*, Yanhong Li*, Zhihua Liu*. Whole-genome Sequencing of 508 Patients Identifies Key Molecular Features Associated With Poor Prognosis in Esophageal Squamous Cell Carcinoma. Cell Research. 2020, 30(10):902-913.  IF=28.1

【6】Zhang Z#, Zhou L#, Xie N#, Nice E. C., Zhang T, Cui Y*, & Huang C*.Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduction and Targeted Therapy. 5(1).(2020).  IF=40.8

【7】Ting Yan#, Heyang Cui#, Yong Zhou#, Bin Yang#, Pengzhou Kong#, Yingchun Zhang#, Yiqian Liu, Bin Wang, Yikun Cheng, Jiayi Li, Shixing Guo, Enwei Xu, Huijuan Liu, Caixia Cheng, Ling Zhang, Ling Chen, Xiaofei Zhuang, Yu Qian, Jian Yang, Yanchun Ma, Hongyi Li, Fang Wang, Jing Liu, Xuefeng Liu, Dan Su, Yan Wang, Ruifang Sun, Shiping Guo, Yaoping Li, Xiaolong Cheng, Zhihua Liu, Qimin Zhan* & Yongping Cui*. Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma. Nature Communications. 2019, 10(1):1670.  IF=14.7

联系邮箱：cuiyp@sphmc.org